Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma
and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and …

TGF-β overexpression is a hallmark of various malignant tumors. This is due to the pivotal
role of TGF-β as it regulates key mechanisms of tumor development, namely …

PURPOSE: NovoTTF-100A is a portable device delivering low-intensity, intermediate
frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF) …

We have recently shown that low intensity, intermediate frequency, electric fields inhibit by
an anti-microtubule mechanism of action, cancerous cell growth in vitro. Using implanted …

Purpose This phase III open-label study compared the efficacy and safety of enzastaurin
versus lomustine in patients with recurrent glioblastoma (WHO grade 4). Patients and …

This randomized, open-label, active-controlled, dose-finding phase IIb study evaluated the
efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection …

Background Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target
of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma …

Purpose: To develop a valid treatment strategy for recurrent high-grade gliomas using
stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide …

Purpose: The DNA repair enzyme O 6-methylguanine DNA methyltransferase (MGMT)
inhibits the killing of tumor cells by alkylating agents, and its loss in cancer cells is …

OBJECTIVE: To assess the feasibility of 5-aminolevulinic acid (5-ALA) fluorescence
guidance for resection of recurrent malignant brain tumors. METHODS: In a multicenter …